Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Erythropoietin counteracts breast cancer treatment with herceptin

16.11.2010
Researchers find erythropoiesis-stimulating drugs cut response to HER2 targeted therapy

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

"Our research indicates when the two drugs were used at the same time, Herceptin was less effective," said study senior author Zhen Fan, M.D., associate professor in MD Anderson's Department of Experimental Therapeutics.

Natural erythropoietin (EPO) controls the body's red blood cell production. Manufactured versions called erythropoietin-stimulating agents or recombinant erythropoietin treat anemia caused by kidney failure and cancer treatment.

"Recombinant erythropoietin is a great drug, and it's saved many lives," Fan said. "Some studies, however, have shown that the drug has effects on cancer cells. We wanted to see if recombinant erythropoietin thwarts Herceptin, based on our understanding of how the two drugs work."

The researchers tested their hypothesis using breast cancer mouse models, then followed up with laboratory experiments on cancer cell lines to work out the molecular details. A retrospective case control study of 111 breast cancer patients supported their findings from the mouse studies.

Human epidermal growth factor receptor-2 (HER2) is overexpressed in 25-30 percent of breast cancers. The drug trastuzumab, known commercially as Herceptin, is an antibody designed to block HER2. Because resistance develops, only about a third of HER2-positive patients respond to the drug.

The presence of functional erythropoietin receptors on HER2-positive breast cancer could be one resistance mechanism, Fan said.

"The whole idea with targeted therapy against the HER2 protein is to shut off the downstream molecular activity launched by HER2," Fan said. "Erythropoietin can activate similar downstream pathways if its receptor is expressed on cancer cells, causing antagonism between the two drugs."

Fan and colleagues demonstrate that when erythropoietin connects with its receptor protein (EpoR), it launches a chain of events that activates Src, a crucial component of a pathway that trastuzumab blocks. It also shuts down a well-known tumor-suppressing gene called PTEN that is believed to be important to trastuzumab's activity against cancer cells.

There is controversy in academic circles about the role and function of EpoR in cancer cells and other types of cells not involved in blood production. It's important to note, Fan said, the team found no evidence that recombinant erythropoietin alone promotes cancer growth.

Tracking down the details

In three HER2-positive breast cancer cell lines, trastuzumab inhibited cell survival and proliferation, while recombinant erythropoietin stimulated cell survival and growth. When the three lines were treated together with trastuzumab and the anemia drug, cell survival increased from 58 percent to 80 percent, 57 percent to 77 percent, and 34 percent to 57.5 percent, respectively.

Two HER2-positive breast cancer cell types were introduced to mice, who then either received mock treatment, trastuzumab only, erythropoietin only or both drugs. Tumors treated with trastuzumab either shrank or stopped growing, with average tumor volume close to zero after 50 days in one cell line and barely registering in another. Growth of tumors treated with erythropoietin closely tracked the control group, increasing rapidly to an average volume of 1,500 cubic millimeters in one line and 600 mm3 in another. Tumors treated with both drugs grew more slowly to about 700 mm3 and 300 mm3.

Improved patient survival in small study

In a retrospective case-control study of patients with HER2-positive breast cancer that had spread, the team compared overall survival and progression-free survival between a group of 37 patients who received trastuzumab plus chemotherapy and recombinant erythropoietin to a matched control group of 74 whose cancer was treated the same way but who received no EPO.

A statistically significant difference in progression-free survival emerged at one year, with 40 percent of the control group having stable disease compared with 19 percent of the erythropoietin group. Overall progression-free survival differences across two years were not statistically significant.

The control group also had better overall survival than the erythropoietin group that was statistically significant in an analysis of multiple variables.

Fan emphasized that clinical findings should be interpreted with caution because the study was small and retrospective. Patients who received erythropoietin might have been sicker than the patients not treated with erythropoietin. Their findings need to be confirmed by larger clinical studies.

"We're expanding this study to include other types of cancer," Fan said. "Of course, different types of cancers are treated with different types of targeted therapies. We need to design our studies using different targeting agents than Herceptin to study whether erythropoietin can antagonize these drugs," Fan said.

Looking forward, Fan said, researchers need to find out why and how some cancer cells express the receptor protein for erythropoietin, and to what extent cancer cells express EpoR. "Recombinant erythropoietin helps to improve a patient's general condition without the need for a blood transfusion," Fan said. "If we can figure out how the expression of the erythropoietin receptor is regulated in cancer cells, we may come up with some new strategies to allow cancer patients to receive the drug for their anemia and fatigue without compromising their treatment with novel targeted therapies, such as anti-HER2 therapy with Herceptin."

The study was funded by a grant from the National Cancer Institute, research awards by the Breast Cancer Research Foundation, and by MD Anderson's Cancer Center Support Grant from from the NCI.

Co-authors with Fan, all from MD Anderson, are first author Ke Liang, Yang Lu, Xinqun Li, M.D., Ph.D., and John Mendelsohn, M.D., all of the department of Experimental Therapeutics; Francisco Esteva, M.D., Ph.D., Giampaolo Bianchini, M.D., Ching-Yi Yang and Gabriel Hortobagyi, M.D., all of the Department of Breast Medical Oncology; Yong Li, Ph.D., Constance Albarracin, M.D., Ph.D., of the Department of Pathology; Katherine Stemke-Hale, Ph.D., and Gordon Mills, M.D., Ph.D., of the Department of Systems Biology; and Chun-Te Chen and Mien-Chie Hung, M.D., Ph.D., of the Department of Molecular and Cellular Oncology.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Life Sciences:

nachricht How brains surrender to sleep
23.06.2017 | IMP - Forschungsinstitut für Molekulare Pathologie GmbH

nachricht A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>